Delivery Order SPE2DB24D2018-SPE2DB25FWWH0
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen injectors, valued at $13,637.01 under a firm fixed price contract. The award, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a non-set-aside competitive procurement. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $31,745.57 to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML pen injectors on July 24, 2025, with completion targeted for July 25, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and is being performed at the contractor's facility in Conshohocken, Pennsylvania. SKYRIZI is a prescription biologic medication used to treat autoimmune and inflammatory conditions, reflecting the federal government's...
- The Defense Logistics Agency awarded a delivery order valued at $113,263.44 to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of SKYRIZI 150 mg/mL pen injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation, with performance to be completed by August 8, 2025, at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $15,904.96 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen injectors. This firm fixed price, non-competitive delivery order was issued on July 29, 2025, with an ultimate completion date of July 30, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. SKYRIZI is a prescription biologic medication used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 ml on-body injectors. This firm fixed-price, competitively awarded contract was issued on July 29, 2025, with an ultimate completion date of August 19, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. SKYRIZI is a biologic immunosuppressant medication used in the treatment of moderate-to-severe plaque psoriasis...
- The Defense Logistics Agency awarded a $47,987.95 firm fixed price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen injectors, with an ultimate completion date of August 25, 2025. This non-set-aside competitive award was issued on August 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic medication used to treat inflammatory skin conditions, and this delivery order represents a specific...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,797.51 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen injectors. This competitive award, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $11,830 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 MG/2.4 ML on-body injector units on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order, which was competitively awarded with no set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a prescription biologic medication used to treat autoimmune conditions, and...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,112.15 for SKYRIZI 150 mg/mL pen injectors under a firm fixed price, non-competitive contract structure. The award was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and performance will be conducted at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under a larger indefinite delivery vehicle. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 26, 2025, for the supply of SKYRIZI 180 mg/1.2 mL on-body injectors valued at $11,830.00. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award based on open competition. The contract will be completed by August 15, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic...
- SPE2DB24D2018Indefinite Delivery Contract
- SPE2DB24D2018-SPE2DB25FWWH0Delivery Order
The Defense Logistics Agency awarded a $14,917.68 delivery order (Contract No. 4569133354) to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of SKYRIZI 150 mg/ml pen injectors. The award represents a firm fixed price delivery order with no set-aside designation, indicating competitive procurement. Performance is scheduled to be completed by August 19, 2025, with fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order functions as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. SKYRIZI is a biologic immunosuppressant medication used to treat autoimmune conditions including plaque psoriasis, psoriatic arthritis, and Crohn's disease. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive portfolio of brand-name and generic medications to support military healthcare programs worldwide through the DLA Medical Supply Chain. The company's extensive federal contract awards demonstrate its capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains at varying transaction values. This award reflects ongoing procurement needs within the Defense Health Agency and broader military medical support infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.9k | 8/18/25 |